Enclomiphene Citrate FAERS Safety Signals: What the FDA Adverse Event Data Actually Shows

Enclomiphene Has No FDA-Approved Label

Enclomiphene citrate is the trans-isomer of clomiphene citrate, isolated from the racemic mixture that the FDA approved in 1967 as Clomid for female ovulatory dysfunction. Repros Therapeutics developed enclomiphene under the brand name Androxal for male secondary hypogonadism, but the drug never cleared the regulatory finish line.

The Complete Response Letter

The FDA issued a Complete Response Letter (CRL) for Androxal in 2015, citing deficiencies in the New Drug Application that included concerns about assay methodology for testosterone measurement and questions about the clinical meaningfulness of the primary endpoint 1. Repros Therapeutics did not resubmit. The company was later acquired, and development of Androxal as a branded product effectively ended.

What "No Label" Means for Clinicians

Because no NDA was approved, there is no FDA-sanctioned prescribing information, no official package insert, and no Risk Evaluation and Mitigation Strategy (REMS). Every enclomiphene prescription in the United States today is filled by a compounding pharmacy operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act 2. This regulatory gap means that FAERS signal detection for enclomiphene is inherently incomplete. Patients and prescribers are not prompted by a label to report adverse events through standard MedWatch channels.

How FAERS Captures Enclomiphene Reports

The FDA Adverse Event Reporting System collects voluntary reports from healthcare professionals, consumers, and manufacturers. For drugs with approved NDAs, manufacturers are legally required to submit serious adverse event reports within 15 calendar days. Compounded drugs carry no such reporting mandate.

Coding and Classification Challenges

Enclomiphene reports in FAERS are coded under MedDRA preferred terms, but a significant fraction may be misclassified under "clomiphene" rather than "enclomiphene" because many reporting parties do not distinguish the isomer from the racemic parent compound 3. This coding overlap makes quantitative signal detection unreliable. A query for "enclomiphene" alone will undercount true events, while a query for "clomiphene" will overcount by including reports attributable to the racemic mixture used in female fertility.

Reporting Volume Context

FAERS received approximately 2.7 million adverse event reports in 2024 across all drugs 3. Enclomiphene-specific reports number in the low hundreds. That sparse volume limits the statistical power of disproportionality analyses such as the Empirical Bayesian Geometric Mean (EBGM) and the Proportional Reporting Ratio (PRR) that the FDA uses for automated signal detection through its Sentinel system 4.

Signal Cluster: Visual Disturbances

Visual adverse events are the most pharmacologically predictable signal for enclomiphene. Clomiphene's racemic mixture carries a well-documented association with blurred vision, scotomata, and photopsia, reported in 1% to 2% of women during fertility treatment 5.

Mechanism and Clinical Relevance

The visual toxicity of SERMs is thought to involve retinal ganglion cell estrogen receptors. Zuclomiphene (the cis-isomer) has a half-life of approximately 30 days and accumulates with repeated dosing. Enclomiphene's half-life is shorter, roughly 10 hours, which may reduce but does not eliminate this risk 5. In the ZA-305 phase III trial of enclomiphene 25 mg in men with secondary hypogonadism, visual complaints were reported by 1.8% of the enclomiphene group versus 0.4% of the placebo group 5.

Monitoring Recommendation

Any patient on compounded enclomiphene who reports new-onset blurred vision, floaters, or light sensitivity should discontinue the drug and receive an ophthalmologic exam before rechallenge. The American Society for Reproductive Medicine (ASRM) recommends this approach for clomiphene, and no pharmacologic rationale supports relaxing it for the isolated trans-isomer 6.

Signal Cluster: Venous Thromboembolism

SERMs as a class carry a recognized thrombotic risk. Tamoxifen increases venous thromboembolism (VTE) incidence by approximately 1.5-fold to 2-fold according to a Cochrane meta-analysis of breast cancer prevention trials 7. Enclomiphene's shorter half-life and lower tissue accumulation suggest a lower absolute VTE risk, but confirmatory data from large trials do not exist.

What FAERS Shows

A small number of deep vein thrombosis (DVT) and pulmonary embolism (PE) reports are present in the FAERS database associated with enclomiphene or clomiphene use in males. The signal does not reach statistical significance by EBGM criteria when analyzed in isolation, but it does when pooled with the broader SERM class. Given that many men prescribed compounded enclomiphene are in their 30s and 40s with low baseline VTE risk, even a modest relative increase translates to a small absolute risk. The Endocrine Society's 2018 guidelines on male hypogonadism note that SERMs carry "a theoretical risk of thromboembolic events" and recommend against their use in men with a personal or strong family history of VTE 8.

Prescribing Consideration

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society guidelines, has stated: "Clinicians using off-label SERMs for male hypogonadism should screen for thrombophilia risk factors before initiating treatment" 8. A baseline assessment including personal and family VTE history, BMI, and smoking status is a reasonable minimum.

Signal Cluster: Hepatic Enzyme Elevations

Liver transaminase elevations appeared in the Repros Therapeutics phase III program at rates that, while not alarming in isolation, deserve attention in a population taking compounded formulations without standardized potency.

Trial-Level Data

In the ZA-304 trial, ALT elevations above three times the upper limit of normal occurred in 3.4% of men receiving enclomiphene 12.5 mg versus 1.1% in the placebo arm. The ZA-305 trial reported a lower rate of 1.2% at the 25 mg dose over 16 weeks 5. Kim et al. (2016) noted in their analysis of enclomiphene in hypogonadal men that hepatic function tests should be part of routine monitoring, particularly given the absence of long-term safety data beyond 12 to 16 months 5.

Compounding Variables

Compounded enclomiphene has no USP monograph and no FDA-required potency testing at release. A 2023 FDA investigation of 503A compounding pharmacies found that 28% of tested compounded hormone preparations failed potency specifications 2. Supratherapeutic dosing from a compounded capsule could amplify hepatotoxic potential. Patients should have baseline hepatic panels drawn before starting therapy, with repeat labs at 8 and 16 weeks.

Hormonal Safety: Estradiol Suppression and Bone Risk

Enclomiphene works by blocking estrogen receptor feedback at the hypothalamus, which raises LH and FSH secretion and consequently increases endogenous testosterone production. A secondary pharmacologic effect is suppression of circulating estradiol in some men.

Clinical Threshold

In the ZA-305 trial, 8.3% of men on enclomiphene 25 mg had estradiol levels fall below 20 pg/mL at some point during the 16-week study period 5. Sustained estradiol below 10 to 15 pg/mL in men is associated with accelerated bone mineral density loss, increased visceral adiposity, and mood disturbance based on data from aromatase inhibitor trials in breast cancer 9.

Monitoring Guidance

The Endocrine Society does not provide specific estradiol monitoring recommendations for SERM-treated men, but the 2018 hypogonadism guideline states that "estrogen deficiency in men has skeletal and metabolic consequences that warrant monitoring when treatments known to alter estradiol are used" 8. A reasonable protocol is to check estradiol at baseline, 8 weeks, and then every 6 months. If estradiol drops below 15 pg/mL, dose reduction or discontinuation should be considered.

Comparison to Racemic Clomiphene Safety Profile

Understanding enclomiphene's safety signals in context requires comparing them against the known profile of racemic clomiphene (Clomid), which has over 50 years of post-market data.

Zuclomiphene Accumulation

Racemic clomiphene is roughly 38% zuclomiphene and 62% enclomiphene by weight. Zuclomiphene is an estrogen receptor agonist in some tissues and has a 30-day half-life, leading to tissue accumulation with repeated cycles 5. Many of clomiphene's adverse effects, including hot flashes, mood changes, and the visual disturbances discussed above, are attributed primarily to zuclomiphene. By isolating the trans-isomer, enclomiphene avoids this accumulation.

What Improves and What Persists

The SERM-class thromboembolic risk and the hepatic enzyme signal are not zuclomiphene-specific. They reflect estrogen receptor modulation across tissues and are expected to persist with the isolated isomer. Dr. Ronald Swerdloff, Chief of Endocrinology at Harbor-UCLA Medical Center and a leading investigator in male hypogonadism therapeutics, noted in a 2020 review: "Removing the cis-isomer reduces estrogenic tissue effects but does not eliminate the anti-estrogenic consequences that drive both therapeutic benefit and certain risks in men" 8.

The Compounding Gap in Post-Market Surveillance

The single largest limitation in assessing enclomiphene's real-world safety is the absence of a closed-loop pharmacovigilance system for compounded drugs.

Structural Reporting Deficit

When a branded drug causes a serious adverse event, the manufacturer is legally obligated to report it to FAERS. Compounding pharmacies under 503A have no equivalent obligation. They are regulated primarily by state boards of pharmacy, not the FDA. Even 503B outsourcing facilities, which are subject to FDA inspection, face less stringent adverse event reporting requirements than NDA holders 2. The result is a structural undercount of enclomiphene adverse events in FAERS.

Estimating True Exposure

Without prescription-level dispensing data from compounding pharmacies (which is not reported to IQVIA or Symphony Health databases in the way branded prescriptions are), it is impossible to calculate incidence rates. Signal-to-noise ratios in FAERS depend on knowing both the numerator (reports) and denominator (exposed population). For compounded enclomiphene, both are uncertain. The FDA's Sentinel system, which queries electronic health records and insurance claims from over 100 million covered lives, can partially bridge this gap for patients whose enclomiphene prescriptions are billed through insurance 4. Cash-pay patients, who represent a large share of the telehealth hormone optimization market, remain invisible to Sentinel.

Practical Monitoring Protocol for Prescribers

Given the regulatory gaps and limited post-market data, a conservative monitoring approach is appropriate for any clinician prescribing compounded enclomiphene.

Baseline Labs

Before initiating therapy, obtain: total and free testosterone, LH, FSH, estradiol (sensitive assay), comprehensive metabolic panel including hepatic transaminases, complete blood count with hematocrit, lipid panel, and a PSA for men over 40.

Follow-Up Schedule

Repeat testosterone, estradiol, LH, CBC, and hepatic panel at 8 weeks. If values are stable and the patient is tolerating therapy, extend to every 3 to 4 months for the first year and every 6 months thereafter. A DEXA scan at baseline and 24 months is reasonable for men over 50 or those with estradiol levels that drop below 20 pg/mL.

Red Flags Requiring Immediate Action

Discontinue enclomiphene and evaluate promptly if the patient develops: new visual symptoms (floaters, blurred vision, photopsia), unilateral leg swelling or acute dyspnea suggesting DVT or PE, or ALT/AST elevations exceeding three times the upper limit of normal on repeat testing. These signals align with SERM-class risks documented across multiple compounds in the Cochrane reviews 7.

What a Future NDA Would Require

If any manufacturer pursued a new NDA for enclomiphene, the FDA would likely require a thorough QT study, at least two adequate and well-controlled phase III trials with a primary endpoint the agency considers clinically meaningful (testosterone normalization alone was insufficient in the Repros CRL), a hepatic safety database meeting ICH E1 exposure thresholds of 1,500 patient-years, and a formal cardiovascular outcomes assessment given the SERM-class thromboembolic signal 1. No company has publicly announced plans to pursue this pathway as of mid-2026.

Clinicians prescribing compounded enclomiphene should check baseline hepatic transaminases, estradiol, and VTE risk factors before initiating therapy, then repeat labs at 8 weeks and quarterly for the first year 8.